Risedronic acid  (Synonyms: Risedronate)

Risedronic acid (Risedronate), a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid inhibits blood stages of Plasmodium falciparum (IC₅₀ of 20.3 μM). Risedronic acid inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins^[1][2][3].

Risedronic acid (0-10 μM; 14 days) suppresses the formation of mineralized nodules in human mesenchymal stem cells (hMSC12) and rat thymus-derived mesenchymal stem cells (ST1BIIb)¹.
Risedronic acid (0-10 μM; 3 days) suppresses the mRNA expression of osteoblast marker gene osteocalcin (OC) in human mesenchymal stem cells (hMSC12)¹.
Risedronic acid (100-1000 μM; 48 h) induces chromatin condensation and activates caspase-3 in human mesenchymal stem cells (hMSC12)¹.
Risedronic acid (Risedronate) (15 μM; 36 h) inhibits isoprenoid biosynthesis in Plasmodium falciparum, as shown by the decreased intensities of bands corresponding to farnesol (FOH) and geranylgeraniol (GGOH)³.
Risedronic acid (15 μM; 36 h) interferes with protein isoprenylation in Plasmodium falciparum, reducing the intensities of farnesylated protein bands and increasing those of geranylgeranylated protein bands³.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Risedronic acid (Risedronate) (30 μg/kg; subcutaneous injection; once every other day; 3 weeks) prevents radiation-induced osteoporosis in female C57BL/6 mice irradiated with 2 Gy X-rays, inhibits trabecular bone loss and microstructural damage, and suppresses the increase in osteoclast number and serum TRAP5b².
Risedronic acid (10-25 mg/kg; intraperitoneal injection; once a day; 7 days) inhibits parasitemia in BALB/c mice infected with Plasmodium berghei strain ANKA, but does not prolong the survival time of mice³.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

283.11

C₇H₁₁NO₇P₂

105462-24-6

Solid

White to off-white

OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=CC=C1

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Fujita H, et al. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells. Basic Clin Pharmacol Toxicol. 2011 Aug;109(2):78-84.  [Content Brief]

  [2]. Willey JS, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010 Jan;46(1):101-11.  [Content Brief]

  [3]. Jordao FM, et al. In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum. Antimicrob Agents Chemother. 2011 May;55(5):2026-31.  [Content Brief]